Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Почему комбинация периндоприл аргинин + индапамид является оптимальным средством нефропротекции при сахарном диабете типа 2?
Почему комбинация периндоприл аргинин + индапамид является оптимальным средством нефропротекции при сахарном диабете типа 2?
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Volpe M. Microalbuminuria Screening in Patients With Hypertension: Recommendations for Clinical Practice. Int J Clin Pract 2008; 62 (1): 97–108.
2. Mailloux LU. Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. Semin Nephrol 2001; 21: 146–56.
3. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens 2004; 17: 986–93.
4. Pedrinelli R, Dell’Omo G, Di Bello V et al. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16: 79–89.
5. Pascual JM, Rodilla E, Gonzalez C. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 2005; 45 (6): 1125–30.
6. Kidney Disease Outcomes Quality Initiative (K/DOQI). Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5) Suppl. 1: S1–290.
7. Susic D. Renal protective potential of antihypertensive drugs. Expert Opin Invest Drugs 2000; 9: 2593–600.
8. Wenzel R. Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy Drugs 2005; 65 (Suppl. 2): 29–39.
9. Ruilope L, Segura J. Renal protection in diabetic patients: benefits of first-line combination of perindopril-indapamide (Preterax). J Hypertens 2006; 24 (Suppl. 3): s9–s12.
10. Mourad J, Le Jeune S. Evaluation of high dose of perindopril/indapamide fixed combination in reducing blood pressure and improving end-organ protection in hypertensive patients Current medical research and opinion 2009; 9 (25): 2271–80.
2. Mailloux LU. Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. Semin Nephrol 2001; 21: 146–56.
3. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens 2004; 17: 986–93.
4. Pedrinelli R, Dell’Omo G, Di Bello V et al. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16: 79–89.
5. Pascual JM, Rodilla E, Gonzalez C. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 2005; 45 (6): 1125–30.
6. Kidney Disease Outcomes Quality Initiative (K/DOQI). Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5) Suppl. 1: S1–290.
7. Susic D. Renal protective potential of antihypertensive drugs. Expert Opin Invest Drugs 2000; 9: 2593–600.
8. Wenzel R. Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy Drugs 2005; 65 (Suppl. 2): 29–39.
9. Ruilope L, Segura J. Renal protection in diabetic patients: benefits of first-line combination of perindopril-indapamide (Preterax). J Hypertens 2006; 24 (Suppl. 3): s9–s12.
10. Mourad J, Le Jeune S. Evaluation of high dose of perindopril/indapamide fixed combination in reducing blood pressure and improving end-organ protection in hypertensive patients Current medical research and opinion 2009; 9 (25): 2271–80.
Авторы
С.В.Недогода
Волгоградский государственный медицинский университет
Волгоградский государственный медицинский университет
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.